ALNYAlnylam Pharmaceuticals, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~25% a year FCF growth. The price demands less than its three-year revenue growth of 53% a year, expectations look modest.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ALNY's price assumes
Alnylam Pharmaceuticals, Inc. trades at 118× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.8 · 6.27× the median: the market pays up for this one
- Price / sales
- 14.7
Price / sales · as of 2025-Q4
- Free cash flow yield
- 1.2%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +25%
Growth the price implies · The price pays for +25% free cash flow growth a year for a decade; revenue has grown +53% a year over the last three.
Details›
- Price / bookas of 2025-Q4
- 69.2
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $465M
- Market capitalisation
- $39.1B
- 3-year revenue growth
- +53%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.